Abstract: Prostate cancer (PCa) is currently the second most common cancer in men worldwide. The current gold standard for diagnosing PCa relies on an ultrasoundguided systematic core needle biopsy indicated after detection changes in a digital rectal examination (DRE) and elevated prostate-specific antigen u(PSA) level in the blood serum. Yet, serum PSA cannot reliably discriminate between benign pathologies and clinically significant forms of PCa. Due to this marker's low specificity, a common problem is over diagnosis, which leads to unnecessary biopsies and over treatment. This is associated with various treatment complications (such as bleeding or infection) and generates unnecessary costs. Therefore, the need for more specific and predictive biomarkers is eminent, to effectively discriminate between aggressive and nonaggressive tumors and to avoid unnecessary prostate biopsies. Biomarkers derived from prostate cancer cells are released into prostatic fluids and then into urine. Urine after manipulation of the prostate is enriched with prostate cancer biomarkers, which include prostate cancer cells, DNAs, RNAs, proteins and other small molecules. Several noninvasive, cost-effective, high-accuracy urinary diagnostic biomarkers such as PSA、PCA3, MALAT1 and miRNA have been developed in recent years. This article reviews the biomarkers for the non-invasive testing of PCa in urine.